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Is Acetylation a Metabolic Rheostat that Regulates 
Skeletal Muscle Insulin Action? 
 
Samuel LaBarge1, Christopher Migdal1, and Simon Schenk1,2,* 
 
 
Skeletal muscle insulin resistance, which increases the risk 
for developing various metabolic diseases, including type 2 
diabetes, is a common metabolic disorder in obesity and 
aging. If potential treatments are to be developed to treat 
insulin resistance, then it is important to fully understand 
insulin signaling and glucose metabolism. While recent 
large-scale “omics” studies have revealed the acetylome to 
be comparable in size to the phosphorylome, the acetylation 
of insulin signaling proteins and its functional relevance to 
insulin-stimulated glucose transport and glucose metabo-
lism is not fully understood. In this Mini Review we discuss 
the acetylation status of proteins involved in the insulin 
signaling pathway and review their potential effect on, and 
relevance to, insulin action in skeletal muscle. 
 
 
INTRODUCTION 
1 
First described by Allfrey and co-workers some 60 years ago as 
a possible means of regulating RNA synthesis, reversible lysine 
acetylation (Ac-Lys) is well conserved across organisms, having 
been described in prokaryotes and eukaryotes (Choudhary et al., 
2014; Kim and Yang, 2011; Verdin and Ott, 2014). Along with 
other post-translational modifications (PTMs; e.g., phosphoryla-
tion, methylation, ubiquitylation), acetylation is one mechanism 
by which the cell refines and enacts a complex control strategy 
in response to varying cellular and physiological processes 
(Choudhary et al., 2014; Verdin and Ott, 2014). Indeed, regula-
tory enzymes that control acetylation have been implicated in 
cancer, cardiovascular disease, neurodegeneration, and type 2 
diabetes (T2D) (Choudhary et al., 2014; Verdin and Ott, 
2014). Lysine acetylation involves the transfer of an acetyl 
group from acetyl-CoA to the ε-amino group in the target ly-
sine. Acetyltransferases (KATs) and deacetylases (DACs) regu-
late this enzymatic process. The twenty identified KATs are split 
into three major families: MOZ YBF2/ SAS3 and TIP60 protein 1 
(MYST), general control of amino acid synthesis protein 5 
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[GCN5] related N-acetyltransferase (GNAT), and CREB binding 
protein/E1A binding protein p300 (CBP/p300) (Berndsen and 
Denu, 2008; Choudhary et al., 2014; Verdin and Ott, 2014). The 
eighteen DACs are categorized in two major families; Zn2+-
dependent and NAD+-dependent (Choudhary et al., 2014; 
Verdin and Ott, 2014). 
Despite the discovery of acetylation 60 years ago and identi-
fication of the first DACs and KATs some 20 years ago, only 
within the last decade has the extent to which acetylation influ-
ences cellular function begun to be appreciated (Choudhary et 
al., 2014; Philip et al., 2014; Verdin and Ott, 2014). A driving 
force behind this transition has been mass spectrometry (MS)-
based proteomic approaches, and the advent of ‘acetylomics’. 
A detailed discussion on MS studies of acetylation and potential 
relevant physiology, including in skeletal muscle, can be found 
elsewhere (Choudhary et al., 2014; Philip et al., 2014; Verdin 
and Ott, 2014). For example, a recent study using high-
resolution MS in 16 rat tissues mapped 15,474 acetyl specific 
modification sites on 4,541 proteins, revealing the acetylome to 
be at least comparable in size to the phosphorylome (Lundby et 
al., 2012). Of particular interest to this Mini Review, pathway 
enrichment analysis in human and rat skeletal muscle identified 
numerous acetylated proteins related to the insulin signaling 
pathway and glucose metabolism (Lundby et al., 2012). And 
because cellular NAD+ and acetyl CoA concentrations change in 
response to perturbations in nutrient and metabolic flux, which 
in turn alters the activity of KATs and NAD+-dependent DACs, 
reversible acetylation provides a natural link between nutrient 
availability and regulation of insulin action. Indeed, brief caloric 
restriction (CR) in humans and rodents potently enhances skel-
etal muscle insulin sensitivity (Kelley et al., 1993; Wang et al., 
2001), with clinical studies demonstrating that the majority of 
the improvement in insulin action during weight loss, or after 
gastric bypass, occurs during the first week of intervention, and 
before substantial weight loss occurs (Assali et al., 2001; 
Gumbs et al., 2005; Kelley et al., 1993). The opposite is also 
true, as short-term hypercaloric feeding rapidly induces skeletal 
muscle insulin resistance (Wang et al., 2001). Conceptually, 
this presents an intriguing physiological model, such that 
changes in food intake are rapidly “translated” into a metabolic 
adaptation (namely insulin action) at the level of skeletal muscle. 
An obvious follow up question being, how is a nutritional cue, at 
the level of food intake, “sensed” and translated into altered 
insulin sensitivity at the level of skeletal muscle? Accordingly, 
the primary focus of this review is on the potential contribution 
of acetylation to regulation of insulin signaling and glucose me-
tabolism in skeletal muscle. 
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THE BASICS OF INSULIN SIGNALING 
 
Canonical insulin signaling is characterized by the step-wise 
progression of kinase phosphorylation, with select phosphatas-
es negatively regulating these kinases. Our focus here is on 
insulin signaling for glucose transport and metabolism through 
Akt-PI3K (phosphoinositide [PI]-3 kinase), which we discuss 
briefly below. A detailed perspective on the nuances of canoni-
cal and non-canonical insulin signaling, can be found else-
where (Cohen, 2006; Leto and Saltiel, 2012; Taniguchi et al., 
2006). 
Regarding insulin signaling for glucose transport, insulin 
binds the extracellular pocket of the transmembrane insulin 
receptor (IR), leading to intrinsic autophosphorylation on its 
cytoplasmic domain (Cohen, 2006; Leto and Saltiel, 2012; 
Taniguchi et al., 2006). The phosphorylated cytoplasmic do-
main of IR recruits and then phosphorylates its downstream 
target, IR substrate (IRS) 1 and/or 2 (Cohen, 2006; Leto and 
Saltiel, 2012; Taniguchi et al., 2006). Upon IRS phosphorylation, 
the PI3K p85/p110 heterodimer is recruited and binds IRS at 
the plasma membrane, where it phosphorylates the plasma 
membrane lipid PI-(4,5)-bisphosphate (PIP2), producing PI-
(3,4,5)-bisphosphate (PIP3). PIP3 binds 3-PI-dependent protein 
kinase-1 (PDK1) and Akt (also known as protein kinase B), 
allowing PDK1 to phosphorylate Akt at Thr308. Subsequently, 
Akt is phosphorylated at Ser473 by mammalian target of 
rapamycin complex 2 (mTORC2), with phosphorylation on 
these two sites being necessary for full Akt activation (Cohen, 
2006; Leto and Saltiel, 2012; Taniguchi et al., 2006). Activated 
Akt phosphorylates numerous downstream substrates leading 
to physiological changes in glucose, lipid, and protein metabo-
lism within the skeletal muscle (Leto and Saltiel, 2012; Tanigu-
chi et al., 2006). Regarding glucose metabolism, Akt-substrate 
of 160 kDa (AS160) and glycogen synthase kinase-3β (GSK3β), 
are two key Akt substrates that facilitate glucose uptake and 
storage, respectively (Cohen, 2006; Leto and Saltiel, 2012; 
Taniguchi et al., 2006). Specifically, Akt phosphorylation of 
AS160 relieves its inhibitory effect on GLUT4 allowing its trans-
location to the plasma membrane, which facilitates glucose 
diffusion into the cell (Stöckli et al., 2011). GSK3β phosphoryla-
tion relieves its inhibition of glycogen synthase (GS), thereby 
promoting glycogenesis (Cohen, 2006). 
 
EFFECTS OF ACETYLATION ON INSULIN SIGNALING  
 
Below we take a step-wise look at the insulin signaling pathway, 
discuss known and proposed effects of acetylation on insulin 
signaling, and postulate the implications for this on insulin-
stimulated glucose transport. A list of known acetylation sites in 
insulin signaling proteins is provided in Table 1. 
 
IR and insulin-like growth factor 1 receptor (IGF1R) 
Significant functional and structural similarities exist between IR 
and IGF1R (Leto and Saltiel, 2012; Taniguchi et al., 2006). In 
recent global acetylation analyses, Lys1088 in IGF1R was acety-
lated in a human myeloid leukemia cell line, MV4-11 
(Choudhary et al., 2009). Interestingly, Lys1088 is in the kinase 
domain of IGFR1, a region that is highly conserved between 
IGF1R and IR, suggesting that this site may be important for 
regulating the function of these proteins (Choudhary et al., 
2009; Pirola et al., 2012). Supporting this, in C2C12 myotubes 
(which is an immortalized muscle-like cell line) inhibition of his-
tone deacetylase 2 (HDAC2) activity increased pIRTyr1146, 
pAktSer473, glucose uptake and glycogen synthesis (Sun and 
Zhou, 2008), although whether this was due to changes in 
acetylation of IR was not assessed. Thus, whether acetylation 
affects the binding of insulin to the receptor or the activity and 
downstream transduction of IR/IGF1 signaling remains to be 
determined. It is important to note that Lys1088 was not identified 
in human skeletal muscle (Choudhary et al., 2009), which per-
haps questions the relevance of this modification to IR or 
IGF1R function in skeletal muscle.  
 
IRS proteins 
Three Ac-Lys sites on IRS1 and four on IRS2 have been identi-
fied (Table 1) (Zhang, 2007; Zhao et al., 2010). Interestingly, 
two Ac-Lys sites (Lys52 and Lys61) in IRS1 lie within the 
pleckstrin homology (PH) domain, which is required for recog-
nizing and binding PIP3. This suggests that acetylation may 
affect how IRS1 recognizes phosphorylated domains in other 
proteins, and therefore insulin signaling through IRS1. In sup-
port of this, in co-immunopreciptiation experiments in liver ly-
sates from Balb/cJJ and ob/ob mice, HDAC2 pulled down with 
IRS1, although this did not occur in lysates from C57BL/6J mice 
(Kaiser and James, 2004). Further supporting a role for acety-
lation in regulating IRS1 function, treatment of the MCF-7 
breast cancer cell line (which has high IRS1 expression) with 
the DAC inhibitor, trichostatin A (TSA), increased both IRS1 
acetylation and insulin-stimulated IRS1 tyrosine phosphoryla-
tion (pIRS1Tyr) (Kaiser and James, 2004). In contrast, phorbol 
myristic acid (PMA), a protein kinase C (PKC) activator, in-
creased HDAC2-IRS1 interaction and reduced insulin-stimulated 
pIRS1Tyr (Kaiser and James, 2004). Lastly, in H4IIE cells, 
SIRT1 inhibitors decreased IRS2 phosphorylation, impaired 
the pAktSer473 insulin signaling response, and subsequent 
mutation of putative Lys118/289/292/412 residues in IRS2 reduced 
insulin-stimulated pIRS2Tyr (Zhang, 2007). Additionally, SIRT2 
has been shown up regulated in insulin resistant C2C12 
myotubes, however its effect on IRS1/2 acetylation state was 
not directly shown (Arora and Dey, 2014). Putting these stud-
ies together, it appears that acetylation of IRS1 and IRS2 has 
opposing effects; IRS1 acetylation promotes its tyrosine 
phosphorylation, whilst acetylation of IRS2 inhibits it. The 
utility of these opposing effects are not readily apparent, it 
presents an interesting paradigm in which two insulin receptor 
substrates require differential modulation of their acetylation 
marks to affect downstream changes.  
 
PI3K 
Class 1A PI3K, a central signaling node for insulin-stimulated 
glucose transport, is a heterodimeric protein that is composed of 
a regulatory subunit (p85α, p85β, p50α, or p55α) and a catalyt-
ic subunit (p110α or p110β) (Taniguchi et al., 2006). MS analy-
sis in non-muscle tissue has identified multiple Ac-Lys residues 
within the regulatory (p85α and p55α) and catalytic (p110β and 
p100γ) subunits (Table 1). For p85α, acetylation sites have 
been identified in the C-terminal SH2 and the inter-SH2 (which 
is between the N- and C-terminal SH2 domains) domains. The-
se regions are important for docking to tyrosine-phosphorylated 
proteins, such as IRS proteins, and also for binding p110. For 
p110, there are no reported acetylation sites on p110α, whilst 
for p110β there are two Ac-Lys sites in close proximity to the 
p85 binding domain and the PI3K ras-binding domain. However, 
whether or not these acetylation marks effect heterodimer for-
mation or PI3K function remains to be determined. In addition, 
to date, in skeletal muscle only the p55α subunit has been 
identified as having an Ac-Lys (Lundby et al., 2012), so clearly 
more detailed work is needed. 
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Table 1. Acetylation sites in the insulin signaling pathway 
Protein Lys-Ac Sites Ref 
Human Mouse Rat 
Insulin Signaling 
IR -- -- -- -- 
IRS1 K52, K61 -- K315 1, 11 
IRS2 -- K118, K289, K292, K412 -- 2, 4, 6 
p85α K530 -- K633 1 
p55α K106, K114 -- -- 1 
p55γ K308 2 
p110β K159, K173 -- -- 1 
p110γ K1000 -- -- 1 
PDK1 K304 K307, K495, K534 K307 1, 2, 7 
mTORC2 K25, K228, K629 K229, K628 K25, K228 1, 2, 4 
Rictor (9)K, K213, K582, K1312 K1311 -- 1, 8 
Akt1 K14, K20, K420, K426 -- -- 1, 7 
Akt2 K378 -- -- 1, 5 
AS160 K477 -- -- 2, 5 
GLUT4 -- -- -- -- 
GSK3β -- -- -- -- 
ACLY (16)K (12)K (17)K 1. 9 
Negative Regulators 
PTEN (7)K, K125, K128 K125, K128 K266 1, 4, 10 
PTP1B K131, K141 -- -- 1 
SKIP -- -- -- -- 
SHIP2 K272 K902 -- 1, 2 
TRB3 -- -- -- -- 
IR, Insulin receptor; IRS1/2, Insulin receptor substrate-1/2; p85, p50, p55, p110, PI3K subunits; PDK1,3-Phosphoinositide dependent protein 
kianse 1, mTORC2, Mammalian target of rapamycin complex 2; Rictor, Raptor independent companion of mTOR; Akt1, v-akt murine thymom 
viral oncogene homolog 1; Akt2, v-akt murine thymom viral oncogene homolog 2; AS160, Akt substrate of 160 kDa; Glut4, Insulin-responsive 
glucose transporter type 4; GSK3β, Glycogen synthase kinase 3 beta; ACLY, ATP-Citrate Lyase; PTEN, Phosphatase and tenisin homolog; 
SKIP, Inositol polyphosphate-5-phosphatase K; SHIP2, Inositol polyphosphate phosphatase-like 1; TRBP3, Tribbles Pseudokinase 3; --, Not 
available. Note: Numbers inside paranthese preceeding, K (Lys), denote the number of Lys-Ac sites identified in each species. (1), 
www.phosphosite.org; (2), Lundby et al, 2012; (3), Choudhary et al 2009; (4), Wang et al 2010; (5), Chen et al 2012; (6), Zhang 2007; (7), 
Sundaresan 2011; (8), Glidden et al 2012; (9), Lin et al 2013; (10), Okomura et al 2006; (11), Zhao, 2010. 
 
 
 
PDK1 and Akt acetylation 
PDK1 and its downstream target, Akt, are serine-theronine 
kinases that recognize the PI3K generated second messenger, 
PIP3, through their pleckstrin homology (PH) domain. Multiple 
acetylation sites have been identified in the kinase and PH 
domain of PDK1 and Akt (Table 1). For example, in cardiac 
myocytes, p300 and p300/CBP-associated factor (PCAF) acet-
ylate lysine residues in the PH domains of Akt (Lys14 and Lys20)  
and PDK1 (Lys495 and Lys534), negatively regulating their inter-
action with PIP3 (Sundaresan et al., 2011). Additionally, in MS 
analysis, Lys378 within the kinase domain of Akt2, was acetylat-
ed. In contrast, SIRT1-mediated deacetylation of these resi-
dues promoted their activation through enhanced binding of Akt 
and PDK1 to PIP3 (Sundaresan et al., 2011) Interestingly, in 
skeletal muscle, there was a decrease in Ac-Akt after insulin 
stimulation in fasted mice (but not non-fasted mice), and con-
comitant greater activation of Akt (Sundaresan et al., 2011). 
While effects on insulin-stimulated glucose uptake were not 
assessed in this study, we (White et al., 2013; 2014) and others 
(Banks et al., 2008) find that overexpression of SIRT1 in skele-
tal muscle does not enhance Akt activation (as measured by 
pAktSer473 and pAktThr308) or insulin sensitivity. In contrast, SIRT1 
is required for the ability of caloric restriction to enhance skele-
tal muscle insulin action, through a mechanism upstream of 
PDK1-Akt, at the level of PI3K (Schenk et al., 2011).  Although 
Ac-Akt was not measured in these studies, overall they do sug-
gest that the contribution of SIRT1 to PDK1-Akt function in 
skeletal muscle is less definitive than in cardiac tissue. 
Interestingly, in non-skeletal muscle cell lines that have nor-
mal insulin-regulated Akt activation, SIRT2, but not SIRT1, 
bound strongly to Akt and appeared to negatively regulate insu-
lin-stimulated Akt activation (Ramakrishnan et al., 2014). Sup-
porting a role for SIRT2 in negatively regulating Akt function, 
SIRT2 expression is increased in insulin resistant C2C12 
myotubes and pharmacological- or knockdown-based inhibition 
of SIRT2 increases insulin signaling, Akt phosphorylation, and 
Acetylation and Skeletal Muscle Insulin Action 
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Table 2. Acetylation and glucose metabolism      
Protein Lys-Ac Sites Ref 
Human Mouse Rat 
Glycolysis 
HK (3)K (4)K (18)K 1, 2, 3 
G6P (12)K (8)K (20)K 1, 2, 3, 4, 5 
PFK (6)K -- (13)K 1, 2, 3, 4, 5 
ALDO (16)K (7)K (14)K 1, 2, 3, 4, 5 
TPI (12)K (12)K (14)K 1, 2, 3, 4, 5 
GAPDH (18)K (14)K (15)K 1, 2, 3, 4, 5 
PGK (29)K (19)K (22)K 1, 2, 3, 4, 5 
PGlyM (3)K (1)K (8)K 1, 2, 3, 4, 5 
ENO (2)K (4)K (17)K 1, 2, 3, 4, 5 
PK (23)K (3)K (12)K 1, 2, 3, 4, 5 
Glycogen 
GCK K296 K296 -- 1, 2 
PGluM (3)K (18)K (14)K 1, 2, 3, 4 
UGP (5)K (13)K (12)K 1, 2, 4 
GS (3)K -- (2)K 1, 2, 4 
GP (4)K (13)K, K470, K796 -- 1, 2, 3, 4, 5, 6  
GLYG -- -- K27, K209, K229 1, 2 
HK, Hexokinase; G6P, Glucose-6-phosphate isomerase; PFK, Phosphofructose-kinase; ALDO, Aldolase; TPI, Triosephosphate isomerase; 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; PGK, phosphoglycerate kinase; PGlyM, phosphoglycerate mutase; ENO, Enolase; PK, 
Pyruvate Kianse; GCK, glucokinase; GS, glycogen synthase; PGluM, phosphoglucose mutase; UGP, UTP-glucose-1-phosphate 
uridyltransferase; GS, Glycogen synthase; GP, Glycogen phosphorylase; GLYG, Glycogenin; H, Human; M, Mouse; R, Rat; --, Not available. 
Note: Numbers inside paranthese preceeding, K (Lys), denote the number of Lys-Ac sites identified in each species. (1) www.phosphosite.org; 
(2), Lundby et al 2012. (3) Choudhary et al 2009. (4) Guan et al 2010. (5) Chen et al 2012; (6), Zhang et al 2012. 
 
 
 
glucose uptake (Arora and Dey, 2014). While SIRT2 was not 
specifically shown to deacetylate Akt in these studies, inhibition 
of SIRT2 in a hepatocellular carcinoma cell line increased Ac-
Akt (Chen et al., 2013). 
 
Negative regulators of insulin signaling 
Phosphatase and tensin homolog (PTEN) negatively regulates 
insulin signaling by dephosphorylating PIP3 (Tamgueny and 
Stokoe, 2007). Multiple Ac-Lys sites are present in the phospha-
tase domain of PTEN (Table 1), and growth factor stimulation in 
HEK293 cells suggest that PCAF-mediated acetylation in this 
domain at Lys125 and Lys128 inhibits its ability to dephosphorylate 
PIP3 (Okumura et al., 2006). In addition, PTEN acetylation is 
increased in SIRT1-deficient embryonic stem cell (ES), suggest-
ing that PCAF and SIRT1 reciprocally regulate PTEN acetylation 
and PIP3 accumulation (Chae and Broxmeyer, 2011). 
Protein tyrosine phosphotase 1B (PTP1B) negatively regu-
lates insulin signaling by dephosphorylating the IR (Klaman et 
al., 2000; Salmeen et al., 2000). Two acetylation sites are pre-
sent in the phosphatase domain of PTP1B (Table 1), although 
whether these activate or inhibit its function is not known. Lastly, 
examination of potential acetylation sites in other negative regu-
lators of insulin signaling such as SKIP2, SHIP and TRB3 (Leto 
and Saltiel, 2012; Taniguchi et al., 2006), reveals that only 
SHIP2 has a known Ac-Lys site (Table 1); its function, however, 
is not known. 
 
mTORC2 
mTOR is a serine-threonine kinase that plays a central role in 
glucose metabolism and insulin signaling (Leto and Saltiel, 2012; 
Shimobayashi and Hall, 2014; Taniguchi et al., 2006). mTORC2, 
which contains the rapamycin-insensitive complex, Rictor, is 
required for Ser473 phosphorylation and full activation of Akt (Leto 
and Saltiel, 2012; Taniguchi et al., 2006). Rictor is a scaffolding 
protein within the mTORC2 complex that is required for proper 
function of mTORC2 activity, and its response to upstream insulin 
signaling (Sarbassov et al., 2005; Shimobayashi and Hall, 2014). 
Rictor contains a central region (amino acids between 1040-
1140) that confers stability to mTORC2 and this region is highly 
acetylated with nine Ac-Lys residues (Table 1); lysine mutants in 
this region of Rictor exhibit impaired pAktSer473  (Glidden et al., 
2012). Additionally, in HEK293 cells p300 overexpression or NAD+-
dependent DAC inhibitors increased acetylation of Rictor, implicat-
ing these proteins in the regulation of Rictor and mTORC2 function. 
 
GLUCOSE METABOLISM 
 
In skeletal muscle, a post-prandial increase in circulating insulin 
normally results in increased glucose uptake into the myocyte, 
of which approximately one-third enters glycolysis and two-
thirds is converted to glycogen (DeFronzo and Tripathy, 2009). 
Thus, coordination and matching of insulin-stimulated glucose 
uptake with this glucose ‘disposal’ is essential. In line with our 
discussions above on insulin signaling, recent MS-based anal-
ysis have found that essentially all enzymes in glycolysis and 
glycogen synthesis contain at least one, and in some cases as 
many as twenty nine, Ac-Lys sites (Table 2) (Choudhary et al., 
2009; Lundby et al., 2012; Wang et al., 2010). While the precise 
role of acetylation to the function of these enzymes, especially 
those that are highly acetylated, remains to be fully elucidated, it 
is not unreasonable to infer that they likely contribute to their 
enzymatic activity. We discuss some examples of this below.
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Samuel LaBarge et al. 
 
 
http://molcells.org  Mol. Cells  301 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gycolysis 
Recently, Lundby et al. (2012) investigated the functional signif-
icance of Ac-Lys in the glycolytic enzymes, aldolase B 
(ALDOB) and glycerol-3-phosphate dehydrogenase (GPD1). 
Lysine to glutamine mutation (which mimics constitutive acety-
lation) ablated enzymatic activity of both enzymes. This finding 
is intriguing as it presents acetylation as a mechanism to slow 
down glycolysis. In contrast, in Salmonella enterica acetylation 
of glycolytic enzymes stimulated glycolysis (Wang et al., 2010). 
While differences between these studies likely lie in, among 
other things, the complexity of the cell type studied, the underly-
ing message is that reversible acetylation of glycolytic enzymes 
is sufficient to modulate their activity.  
 
Glycogen synthesis 
Glycogen phosphorylase (GP) breaks down glycogen by catalyz-
ing the reaction of glycogen to glucose-1-phosphate (Wang et al., 
2010). GP is classically thought to be regulated by phosphorylation 
through the opposing actions of phosphorylase kinase (PK) and 
protein phosphatase 1 (PP1). While PP1 acetylation sites have been 
identified (Choudhary et al., 2009; Lundby et al., 2012), the interplay 
of phosphorylation and acetylation on the activity of PP1 or its targets 
is unclear. Recently, GP Lys470 and Lys796 acetylation were found to 
negatively regulate glycogen catabolism by promoting PP1-GP inter-
action through the substrate targeting subunit GL, which leads to GP 
dephosphorylation and inhibition of its activity; however, the KAT 
responsible was not identified (Zhang et al., 2012). Additionally, 
pGSK3βSer9 was reduced in GH3 cells treated with resveratrol, a 
SIRT1 innibitor, although the mechanism underlying this effect is 
unknown (Monteserin-Garcia et al., 2013). Taken together, these 
results infer that insulin activation leads to acetylation of GP and 
deacetylation of GSK3β, thereby facilitating glycogen storage. 
COORDINATING AND MATCHING CYTOSOLIC 
PROTEIN ACETYLATION TO GLUCOSE DISPOSAL 
 
From our discussions above, it is clear that there are many 
cytosolic proteins that undergo reversible acetylation. Given 
that acetyl CoA is primarily generated in the mitochondria, a 
key question is of course, how is acetyl CoA generated in the 
cytosol to meet requirements for acetylation of proteins found 
within the cytosol? Citrate generated from the tricarboxylic acid 
(TCA) cycle is shuttled from the mitochondria into the cytosol 
when citrate begins to accumulate, where it is cleaved in the 
cytosol by ATP citrate lyase (ACLY) to produce acetyl CoA 
(Elshourbagy et al., 1992). Thus, production of cytosolic acetyl 
CoA would increase under conditions of increased glucose flux, 
such as with insulin stimulation. Interestingly, ACLY is directly 
phosphorylated by Akt, which increases its activity (Berwick et 
al., 2002; Migita et al., 2008; Pierce et al., 1982). Moreover, 
PCAF-mediated acetylation of ACLY at Lys540/546/554 stabilizes 
the protein (Lin et al., 2013). Putting these findings together, 
regulation of ACLY by Akt and acetylation presents an elegant 
model of matching insulin-stimulated Akt activation and glucose 
uptake to generation of cytosolic acetyl CoA and subsequent 
acetylation of cytosolic proteins. 
 
ACETYLATION AS A METABOLIC RHEOSTAT: TYING 
THE PIECES TOGETHER  
 
Traditionally, insulin signaling to glucose transport has been 
thought to progress via stepwise phosphorylation. The advent 
of the ‘acetylome’, however, provides an exciting additional 
level of control; such that perturbations in glucose flux are di-
rectly linked to changes in the activity (or binding) of insulin 
Fig. 1. Theoretical overview of acetylation in
insulin signaling and glucose metabolism. (A)
KATs and DACs have been shown to regulate
the acetylation patterns of various proteins with-
in the insulin signaling pathway. However, the
exact pattern of acetylation and the effect acety-
lation plays in response to insulin stimulation is
not known. (B) Acetylation within glucose me-
tabolism has been shown to regulate glycolytic
enzymes and promote glycogen synthesis.
However, the dynamics of acetylation patterns
within these pathways, and the KATs and DACs
that regulate them, following insulin stimulation,
are not known. (C) Insulin stimulation may acti-
vate ACLY within the cytosol that produces
acetyl CoA, from Citrate, required for subse-
quent acetylation of target proteins.  
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signaling proteins and enzymes central to glucose disposal or 
protein function, through changes in cytosolic acetyl CoA and 
NAD+ levels. By extension this presents a fascinating, but per-
haps not surprising model in which acetylation allows for glu-
cose availability to “talk” to proteins in a manner that allows 
prompt, flexible modulation of enzyme activity and pathway flux. 
The end result being a transient increase in glucose disposal 
after insulin stimulation that is in time down-regulated once the 
cell is sufficiently “full”.  
While it is easy to ascribe a simple “on” or “off” tag to the ef-
fects of acetylation on function, acetylation does not appear 
binary, but rather a mechanism by which the cell finely tunes its 
response to insulin. One might think of phosphorylation as the 
key that turns the engine on or off, whilst acetylation is the ac-
celerator and brake that by extension controls speed (or flux) 
across a wide spectrum. This is perhaps supported by the fact 
that many of the proteins in glycolysis are heavily acetylated, 
thereby providing stepwise control of glucose uptake in con-
junction with insulin signaling. 
We present a theoretical overview of this in Fig. 1. The trans-
location of GLUT4 to the plasma membrane is central to insu-
lin-stimulated glucose transport. Under physiological conditions, 
the number of GLUT4 vesicles recruited to the membrane is a 
function of the efficiency of insulin signaling. Moreover, mainte-
nance of the interstitial-to-intracellular glucose gradient is es-
sential to maintain glucose transport through GLUT4 after insu-
lin stimulation. In skeletal muscle, this gradient is maintained by 
conversion of glucose to glucose-6-phosphate (G6P), by hexo-
kinase II (HKII). Once inside the muscle cell, glucose is dis-
posed of oxidatively or non-oxidatively, via glycolysis or glyco-
gen synthesis, respectively, with approximately two-thirds of 
glucose being shuttled toward glycogen. Thus, if one ascribes 
that acetylation of glycolytic enzymes results in a general slow-
ing of reaction rates, then there would be an accumulation of 
intracellular G6P and reduced glucose transport. If concurrently, 
however, acetylation of glycogen-related enzymes favors gly-
cogen synthesis, then G6P will be incorporated into glycogen, 
and a picture of flexible coordination of glucose disposal toward 
glycogen synthesis is revealed. Parallel changes in the cyto-
solic availability of acetyl CoA and NAD+, as a function of glu-
cose flux, would allow for rapid temporal control of the flow of 
glucose, as well as simultaneous modulation of the acetylation 
status of insulin signaling proteins. The end result being coordi-
nated control of insulin signaling, with glucose uptake and glu-
cose disposal by acetylation. Certainly, the fact that insulin 
stimulation leads to activation of ACLY adds credence to this 
line of thinking. 
In this Minireview our goal has been to extrapolate the im-
portance of acetylation to the regulation of insulin-stimulated 
glucose uptake and glucose metabolism, with a primary focus on 
skeletal muscle. Our reason for focusing on skeletal muscle is 
two-fold: skeletal muscle is the primary site for glucose disposal 
in the post-prandial state, and impairments in this disposal is a 
key predictor for the development of many metabolic diseases, 
including type 2 diabetes (DeFronzo and Tripathy, 2009). Thus, if 
we can understand “if and how” acetylation affects insulin signal-
ing and glucose metabolism in muscle, then more effective 
treatment can be developed. Overall, however, there are clearly 
more questions than answers. One major issue in extrapolating 
to skeletal muscle is that many of the to-date identified Ac-Lys 
residues in the insulin signaling pathway (but not glucose metab-
olism) were not identified in human skeletal muscle (Choudhary 
et al., 2009; Lundby et al., 2012). Part of the reason for this could 
be that the muscle tissue was not insulin-stimulated, which might 
limit overall coverage. As such, it will be very interesting in future 
studies to compare the acetylome of basal vs. insulin-stimulated 
muscle, our hypothesis being that more proteins will be revealed 
to be acetylated after insulin stimulation. As part of this, determin-
ing if different patterns of acetylation exist between insulin sensi-
tive compared to insulin resistant muscle, and whether this is 
altered by interventions that enhance insulin action, such as 
caloric restriction or exercise, will be highly insightful. For in-
stance, in rat skeletal muscle, the acetylation of proteins is 
higher in aged/insulin resistant vs. young/insulin sensitive rats, 
whilst exercise normalizes acetylation in aged muscle to a level 
seen in young (Koltai et al., 2010); whether or not any of these 
proteins are related to insulin signaling or glucose metabolism 
is unknown. 
Another pressing question is, does acetylation of insulin sig-
naling proteins in skeletal muscle modulate their function? In 
addition, very little data exists regarding the specific KATs and 
DACs that regulate Ac-Lys residues of the enzymes and pro-
teins of insulin signaling and glucose metabolism, let alone the 
acetylome as a whole. Furthermore, the discovery of various 
other lysine acylations, such as malonylation, succinylation, 
proprionylation, provide an additional link between nutrient flux 
and protein function (Choudhary et al., 2014). Studies using 
pharmacological or gene-based approaches, in parallel with 
‘omics analysis and measurement of insulin-stimulated glucose 
uptake will be most helpful in addressing these gaps in 
knowledge. 
In conclusion, in this review we examined the exciting topic of 
acetylation as an additional regulatory pathway in insulin signal-
ing and glucose metabolism. Clearly ‘omics analysis has un-
locked the door to the acetylome, and as a result, it is tempting 
to extrapolate functional outcomes (in our case, insulin action) 
from changes in protein and enzyme acetylation. Without doubt, 
however, many questions remain to be answered before the 
door is fully opened, and we look forward to exciting discoveries 
in the coming years.  
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